110 related articles for article (PubMed ID: 15242360)
21. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
Lim LS; Sherin K;
Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
[TBL] [Abstract][Full Text] [Related]
22. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists.
Hollingsworth JM; Hollenbeck BK; Daignault S; Kim SP; Wei JT
J Urol; 2009 Nov; 182(5):2410-4. PubMed ID: 19765742
[TBL] [Abstract][Full Text] [Related]
23. [Prostate-specific antigen in the diagnosis of prostate cancer in Denmark].
Andreassen LA; Vondeling H
Ugeskr Laeger; 2006 Jan; 168(5):475-7. PubMed ID: 16472437
[TBL] [Abstract][Full Text] [Related]
24. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country.
Kuo NW; Lin HC; Lee HC
J Urol; 2008 Nov; 180(5):1954-8; discussion 1958. PubMed ID: 18801533
[TBL] [Abstract][Full Text] [Related]
25. Relative importance of PSA in prostate cancer treatment.
Unger HA; Kane RD; Fox KM; Gandhi S; Alzola C; Lamerato L; Newling D; Kumar S
Urol Oncol; 2005; 23(4):238-45. PubMed ID: 16018938
[TBL] [Abstract][Full Text] [Related]
26. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
27. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.
Penson D; Moul J; Gandhi S; Newling D
Urology; 2006 Jul; 68(1):80-4. PubMed ID: 16777198
[TBL] [Abstract][Full Text] [Related]
28. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
29. [The general practitioner's part in the initiation of diagnostic procedures in prostate cancer].
Braun KP; May M; Grassmel Y; Führer S; Hoschke B; Braun V
Aktuelle Urol; 2008 Mar; 39(2):141-6. PubMed ID: 18379968
[TBL] [Abstract][Full Text] [Related]
30. Prostate biopsy: who, how and when. An update.
Djavan B; Milani S; Remzi M
Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
[TBL] [Abstract][Full Text] [Related]
31. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
[TBL] [Abstract][Full Text] [Related]
32. Assessment of American urologists' approach to hormonal management of prostate cancer.
Warren KS; Osborn J; Chodak GW
Urology; 2006 Dec; 68(6):1305-7. PubMed ID: 17169651
[TBL] [Abstract][Full Text] [Related]
33. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
34. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
35. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.
Vicini FA; Vargas C; Abner A; Kestin L; Horwitz E; Martinez A
J Urol; 2005 May; 173(5):1456-62. PubMed ID: 15821460
[TBL] [Abstract][Full Text] [Related]
36. Variations in the use of prostate cancer staging tests: results from one NCCN Institution.
Bennett CL; Yang T; Nadler R
Oncology (Williston Park); 1997 Nov; 11(11A):155-7. PubMed ID: 9430186
[TBL] [Abstract][Full Text] [Related]
37. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
38. Differences between urologists in United States and Canada in approach to bladder cancer.
Chung D; Hersey K; Fleshner N
Urology; 2005 May; 65(5):919-25. PubMed ID: 15882724
[TBL] [Abstract][Full Text] [Related]
39. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
